SIREN : 442906608
SCI MEDI LARIVOT is a French company founded 23 years ago, specialized in the sector Supports juridiques de programmes. Based in MATOURY (97351), this company of category PME shows in 2024 a net income positive of 72 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 |
|---|---|---|
| Revenue | N/C | N/C |
| Net income | 71 565 € | 57 127 € |
| EBITDA | N/C | N/C |
| Net margin | N/C | N/C |
In 2024, SCI MEDI LARIVOT generates positive net income of 72 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2023-2024: 57 k€ -> 72 k€.
71 565 €
The debt ratio (= Financial debt / Equity x 100) stands at 9%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 87%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
9.254%
86.714%
31.6%
In 2024, the debt ratio of SCI MEDI LARIVOT (9.25) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of SCI MEDI LARIVOT (86.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
The liquidity ratio (= Current assets / Current liabilities) stands at 337.71. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
337.713
In 2024, the liquidity ratio of SCI MEDI LARIVOT (337.71) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Based on 80 transactions of similar company sales
(all years),
the value of SCI MEDI LARIVOT is estimated at
168 070 €
(range 52 209€ - 462 429€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 80 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SCI MEDI LARIVOT with other companies in the same sector:
Voir toutes les statistiques du secteur Supports juridiques de programmes
The revenue of SCI MEDI LARIVOT is not publicly disclosed (confidential accounts filed with INPI).
Yes, SCI MEDI LARIVOT generated a net profit of 72 k€ in 2024.
The headquarters of SCI MEDI LARIVOT is located in MATOURY (97351), in the department Guyane.
The tax return of SCI MEDI LARIVOT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SCI MEDI LARIVOT operates in the sector Supports juridiques de programmes (NAF code 41.10D). See the 'Sector positioning' section above to compare the company with its competitors.